Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.

about

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.

Item

http://www.wikidata.org/entity/Q47105124

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efficacy and safety of regoraf ...... ib treatment: A meta-analysis.

@en

Efficacy and safety of regoraf ...... ib treatment: A meta-analysis.

@nl

type

Item

label

Efficacy and safety of regoraf ...... ib treatment: A meta-analysis.

@en

Efficacy and safety of regoraf ...... ib treatment: A meta-analysis.

@nl

prefLabel

Efficacy and safety of regoraf ...... ib treatment: A meta-analysis.

@en

Efficacy and safety of regoraf ...... ib treatment: A meta-analysis.

@nl

P1476

Efficacy and safety of regoraf ...... ib treatment: A meta-analysis.

@en

P2093

Daxun Piao

http://www.w3.org/2001/XMLSchema#string

Tao Jiang

http://www.w3.org/2001/XMLSchema#string

Wensheng Wang

http://www.w3.org/2001/XMLSchema#string

Zhenan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies

Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program

Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.

P304

e8698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1097/MD.0000000000008698

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29310342

http://www.w3.org/2001/XMLSchema#string

P932

5728743

http://www.w3.org/2001/XMLSchema#string